Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
1.580
-0.010 (-0.63%)
At close: Apr 28, 2026, 4:00 PM EDT
1.590
+0.010 (0.62%)
After-hours: Apr 28, 2026, 7:18 PM EDT
PACB Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for PACB stock have an average target of 1.67, with a low estimate of 1.00 and a high estimate of 2.00. The average target predicts an increase of 5.70% from the current stock price of 1.58.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for PACB stock from 3 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 4 | 3 | 3 | 3 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Sell Maintains $1.5 → $1 | Sell | Maintains | $1.5 → $1 | -36.71% | Apr 14, 2026 |
| Barclays | Barclays | Hold → Sell Downgrades $2 → $1.5 | Hold → Sell | Downgrades | $2 → $1.5 | -5.06% | Mar 6, 2026 |
| Barclays | Barclays | Hold Maintains $1.5 → $2 | Hold | Maintains | $1.5 → $2 | +26.58% | Dec 15, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $1.5 → $2 | Hold | Maintains | $1.5 → $2 | +26.58% | Nov 11, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Maintains $1.8 → $2 | Buy | Maintains | $1.8 → $2 | +26.58% | Nov 10, 2025 |
Financial Forecast
Revenue This Year
178.11M
from 160.01M
Increased by 11.32%
Revenue Next Year
199.74M
from 178.11M
Increased by 12.14%
EPS This Year
-0.52
from -1.82
EPS Next Year
-0.42
from -0.52
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 186.9M | 210.0M | |||||
| Avg | 178.1M | 199.7M | |||||
| Low | 169.0M | 186.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 16.8% | 17.9% | |||||
| Avg | 11.3% | 12.1% | |||||
| Low | 5.6% | 4.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | -0.49 | -0.25 | ||||
| Avg | -0.52 | -0.42 | ||||
| Low | -0.52 | -0.46 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.